{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:24:41Z","timestamp":1792549481889,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204265"],"award-info":[{"award-number":["82204265"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001737","name":"Lady Davis Fellowship Trust, Hebrew University of Jerusalem","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006260","name":"Technion-Israel Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Theoretical Biology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtbi.2025.112263","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:09:18Z","timestamp":1757030958000},"page":"112263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Mathematical model suggests current CAR-macrophage dosage is efficient to low pre-infusion tumour burden but refractory to high tumour burden"],"prefix":"10.1016","volume":"616","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9081-331X","authenticated-orcid":false,"given":"Shilian","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0953-9673","authenticated-orcid":false,"given":"Maoxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtbi.2025.112263_b0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jlb.64.4.419","article-title":"Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives","volume":"64","author":"Andreesen","year":"1998","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jtbi.2025.112263_b0010","doi-asserted-by":"crossref","unstructured":"Anthony-Gonda, K., et al., Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Science Translational Medicine, 2019. 11(504): p. eaav5685.","DOI":"10.1126\/scitranslmed.aav5685"},{"issue":"10297","key":"10.1016\/j.jtbi.2025.112263_b0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jtbi.2025.112263_b0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/clinids\/11.3.361","article-title":"Inoculum effect","volume":"11","author":"Brook","year":"1989","journal-title":"Rev. Infect. Dis."},{"issue":"6","key":"10.1016\/j.jtbi.2025.112263_b0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0030","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","article-title":"The application of HER2 and CD47 CAR-macrophage in ovarian cancer","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0270-0255(87)90071-6","article-title":"A mathematical model of monoclonal antibody therapy in leukemia","volume":"9","author":"Dillman","year":"1987","journal-title":"Mathematical Modelling"},{"issue":"5","key":"10.1016\/j.jtbi.2025.112263_b0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41587-020-0520-5","article-title":"Cancer-eating immune cells kitted out with CARs","volume":"38","author":"Dolgin","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.jtbi.2025.112263_b0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","article-title":"Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer","volume":"129","author":"Dong","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.jtbi.2025.112263_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009822","article-title":"Classical mathematical models for prediction of response to chemotherapy and immunotherapy","volume":"18","author":"Ghaffari Laleh","year":"2022","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.jtbi.2025.112263_b0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.omtm.2022.04.007","article-title":"Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR Tcells with CMV vaccine","volume":"25","author":"Guan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","article-title":"The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors","volume":"11","author":"Hadiloo","year":"2023","journal-title":"Biomarker Res."},{"issue":"8","key":"10.1016\/j.jtbi.2025.112263_b0065","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgad243","article-title":"Titrating CD47 by mismatch CRISPR-interference reveals incomplete repression can eliminate IgG-opsonized tumors but limits induction of antitumor IgG","volume":"2","author":"Hayes","year":"2023","journal-title":"PNAS Nexus"},{"issue":"5","key":"10.1016\/j.jtbi.2025.112263_b0070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/PL00006671","article-title":"Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon \u03b3 and lipopolysaccharide","volume":"45","author":"Hennemann","year":"1997","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.jtbi.2025.112263_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07649","article-title":"Bispecific antibodies: A guide to model informed drug discovery and development","volume":"7","author":"Kareva","year":"2021","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.jtbi.2025.112263_b0080","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0090","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.jtbi.2025.112263_b0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005360","article-title":"Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse","volume":"10","author":"Liu","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","article-title":"Strategies to enhance CAR-T persistence","volume":"10","author":"Liu","year":"2022","journal-title":"Biomarker Res."},{"issue":"22","key":"10.1016\/j.jtbi.2025.112263_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223692","article-title":"CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.jtbi.2025.112263_b0115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2014364118","article-title":"Inoculum effect of antimicrobial peptides","volume":"118","author":"Loffredo","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jtbi.2025.112263_b0120","article-title":"Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.jtbi.2025.112263_b0125","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1172\/JCI59832","article-title":"Evidence for bistable bacteria-neutrophil interaction and its clinical implications","volume":"122","author":"Malka","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jtbi.2025.112263_b0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.jtbi.2025.112263_b0135","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtbi.2025.112263_b0140","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"issue":"26","key":"10.1016\/j.jtbi.2025.112263_b0145","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jtbi.2025.112263_b0150","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.20170355","article-title":"The fate and lifespan of human monocyte subsets in steady state and systemic inflammation","volume":"214","author":"Patel","year":"2017","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0155","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"issue":"16_suppl","key":"10.1016\/j.jtbi.2025.112263_b0160","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1200\/JCO.2022.40.16_suppl.2533","article-title":"A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors","volume":"40","author":"Reiss","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"162","key":"10.1016\/j.jtbi.2025.112263_b0165","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2019.0734","article-title":"Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data","volume":"17","author":"Sahoo","year":"2020","journal-title":"J. R. Soc. Interface"},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-cancerbio-061421-012235","article-title":"Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies","volume":"7","author":"Salas-Benito","year":"2023","journal-title":"Ann. Rev. Cancer Biol."},{"key":"10.1016\/j.jtbi.2025.112263_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fsysb.2022.923085","article-title":"A Mathematical Model for On-Target Off-Tumor Effect of CAR-T Cells on Gliomas","volume":"2","author":"Santurio","year":"2022","journal-title":"Front. Syst. Biol."},{"issue":"8","key":"10.1016\/j.jtbi.2025.112263_b0180","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.jtbi.2025.112263_b0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.jtbi.2025.112263_b0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1084\/jem.128.3.415","article-title":"THE ORIGIN AND KINETICS OF MONONUCLEAR PHAGOCYTES","volume":"128","author":"van Furth","year":"1968","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jtbi.2025.112263_b0195","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/19420862.2016.1141160","article-title":"The application of mathematical modelling to the design of bispecific monoclonal antibodies","volume":"8","author":"van Steeg","year":"2016","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.jtbi.2025.112263_b0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.thj.6200557","article-title":"Effect of adenovirus-mediated p27 gene expression on the proliferation and apoptosis of HL-60 and Raji cell lines","volume":"5","author":"Wang","year":"2004","journal-title":"Hematol. J."},{"key":"10.1016\/j.jtbi.2025.112263_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103873","article-title":"CAR-macrophage: An extensive immune enhancer to fight cancer","volume":"76","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.jtbi.2025.112263_b0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11538-024-01334-9","article-title":"Modelling Role of Protective and Nonprotective HLA Allele Inducing Different HIV Infection Outcomes","volume":"86","author":"Xu","year":"2024","journal-title":"Bull. Math. Biol."},{"issue":"1","key":"10.1016\/j.jtbi.2025.112263_b0215","doi-asserted-by":"crossref","first-page":"25557","DOI":"10.1038\/s41598-024-75971-4","article-title":"Bispecific antibody (ABL602 2\u2009+\u20091) induced bistable acute myeloid leukemia kinetics","volume":"14","author":"Xu","year":"2024","journal-title":"Sci. Rep."}],"container-title":["Journal of Theoretical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519325002292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519325002292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:02:05Z","timestamp":1772834525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022519325002292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"alternative-id":["S0022519325002292"],"URL":"https:\/\/doi.org\/10.1016\/j.jtbi.2025.112263","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.08.28.25334697","asserted-by":"object"}]},"ISSN":["0022-5193"],"issn-type":[{"value":"0022-5193","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mathematical model suggests current CAR-macrophage dosage is efficient to low pre-infusion tumour burden but refractory to high tumour burden","name":"articletitle","label":"Article Title"},{"value":"Journal of Theoretical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtbi.2025.112263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112263"}}